Can CBD replace antipsychotics for cannabis users with psychosis?
NCT ID NCT04105231
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares cannabidiol (CBD) to the standard antipsychotic risperidone in 64 adults with schizophrenia or related psychotic disorders who have used cannabis. The goal is to see if CBD can reduce psychotic symptoms and help people stop or cut down cannabis use. Participants receive either CBD or risperidone for several weeks, and their symptoms and cannabis use are tracked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANNABIS INDUCED PSYCHOTIC DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Neuropsychiatric Schizophrenia Research
Glostrup Municipality, 2600, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?